First human test for promising liver disease drug begins
NCT ID NCT06705998
Summary
This is the first study testing a new drug called BAR502 in humans. Researchers will give the drug to 52 healthy volunteers to check if it's safe and see how the body processes it. The goal is to gather basic information to potentially develop a treatment for NASH, a serious liver disease, but this early study won't treat patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CROSS Research S.A. Phase I Unit
RECRUITINGArzo, CH-6864, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.